Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2021 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic...
August 02, 2021 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ending June 30, 2021 and recent company developments,...
July 28, 2021 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 2, 2021 at 8:30 AM ET to discuss results for...
July 09, 2021 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a...
June 29, 2021 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy, PhD

NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced with great sadness the passing of longtime Board Member, William J. Kennedy, PhD. “It is with deep...
June 18, 2021 14:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials...
June 18, 2021 07:35 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Company’s investigational once-daily, oral BTK...
June 11, 2021 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy...
June 09, 2021 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma...
June 04, 2021 09:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19) Triple combination of ublituximab and UKONIQ (U2) + TG-1701 cohort (n=19) resulted in 79% ORR, with 21% CR rate,...